VivoSeq
Other

Tonsillitis

19

Pipeline Programs

1

Active Trials

10

Companies Involved

Tonsillitis is an emerging landscape with 19 programs across 10 companies. The most active players are Sanofi, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Fresenius Kabi Oncology Ltd.. 12 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

57/100

Attrition Rate

30/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

10

clinical trials

Completed4 · 40%
Terminated3 · 30%
Unknown status2 · 20%
Active, not recruiting1 · 10%

Trial Activity

10 trials

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults
Terminated·Sanofi logoSanofi·Phase 3·NCT00315549·233 enrolled
TELI TON - Telithromycin in Tonsillitis
Terminated·Sanofi logoSanofi·Phase 3·NCT00315042·314 enrolled
Bacteriological Study of Acute Follicular Tonsillitis
Unknown status··N/A·NCT04321733·66 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)